Request for Project Proposals

Solicitation Number: MTEC-20-09-COVID-19_Treatment_MIDRP
“Development of Treatments for COVID-19”

Issued by:
Advanced Technology International (ATI),
MTEC Consortium Manager (CM)
315 Sigma Drive
Summerville, SC 29486
for the
Medical Technology Enterprise Consortium (MTEC)

Request Issue Date: March 25, 2020

Enhanced White Paper Due Date: April 8, 2020
Noon Eastern Time Zone
Table of Contents

1  Executive Summary .................................................................................................................. 3
  1.1. The Medical Technology Enterprise Consortium ......................................................... 3
  1.2. Purpose ............................................................................................................................. 3

2  Administrative Overview ......................................................................................................... 4
  2.1. Request for Project Proposals (RPP) .............................................................................. 4
  2.2. Funding Availability and Type of Funding Instrument Issued ........................................... 4
  2.3. Acquisition Approach ....................................................................................................... 4
  2.4. MTEC Member Teaming.................................................................................................... 5
  2.5. Proprietary Information .................................................................................................... 6
  2.6. Offeror Eligibility .............................................................................................................. 6
  2.7. Inclusion of Nontraditional Defense Contractors or Nonprofit Research Institutions .... 6
  2.8. Nontraditional Defense Contractor Definition .................................................................. 7
  2.9. Cost Sharing Definition .................................................................................................... 7
  2.10. MTEC Assessment Fee .................................................................................................. 8
  2.11. Intellectual Property and Data Rights ............................................................................ 9
  2.12. Expected Award Date .................................................................................................... 10
  2.13. Anticipated Enhanced White Paper Selection Notification ........................................... 10

3  Enhanced White Paper ............................................................................................................. 10
  3.1. Enhanced White Paper Rationale .................................................................................... 10
  3.2. Enhanced White Paper Submission ................................................................................ 10
  3.3. Submission Format........................................................................................................... 11

4  Enhanced White Paper Preparation Instructions ..................................................................... 11
  4.1. General Instructions .......................................................................................................... 11

5  Technical Requirements .......................................................................................................... 11
  5.1. Introduction ....................................................................................................................... 11
  5.2. Scope of Work ................................................................................................................... 11
  5.3. Potential Follow-On Tasks .............................................................................................. 12
  5.4. Restrictions on Animal and Human Subjects .................................................................... 13

6  Enhanced White Paper Preparation .......................................................................................... 13
  6.3. Step 2: Cost Proposal (for Only Those Offerors Recommended for Funding) ............... 15
  6.4. Freedom of Information Act (FOIA) ............................................................................... 16
  6.5. Enhanced White Paper and Cost Proposal Preparation Costs ....................................... 16

7  Selection ................................................................................................................................ 16
  7.1 Best Value .......................................................................................................................... 17

8  Points-of-Contact .................................................................................................................... 18

9  Acronyms/Abbreviations ......................................................................................................... 18

10 Enhanced White Paper Template .......................................................................................... 20
1 Executive Summary

1.1. The Medical Technology Enterprise Consortium
The Medical Technology Enterprise Consortium (MTEC) is an enterprise partnership in collaboration with industry and academia to facilitate research and development activities, in cooperation with the U.S. Army Medical Research and Development Command (USAMRDC) and other DoD agencies in the biomedical sciences (including but not limited to drugs, biologics, vaccines, medical software and medical devices) to protect, treat and optimize the health and performance of U.S. military personnel. MTEC is a nonprofit corporation with the following principal objectives:

(a) biomedical research and prototyping;
(b) exploration of private sector technology opportunities;
(c) technology transfer; and
(d) deployment of intellectual property (IP) and follow-on production.

MTEC is openly recruiting members to join a broad and diverse biomedical consortium that includes representatives from large businesses, small businesses, contract research organizations, “nontraditional” defense contractors, academic research institutions and not-for-profit organizations; for more information on the MTEC mission, see the Proposal Preparation Guide (PPG) and MTEC website.

MTEC operates under an Other Transaction Agreement (OTA) for prototypes with USAMRDC. As defined in the OTA Guide dated November 2018, a prototype project addresses a proof of concept, model, reverse engineering to address obsolescence, pilot, novel application of commercial technologies for defense purposes, agile development activity, creation, design, development, demonstration of technical or operational utility, or combinations of the foregoing. A process, including a business process, may be the subject of a prototype project. Although assistance terms are generally not appropriate in OT agreements, ancillary work efforts that are necessary for completion of the prototype project, such as test site training or limited logistics support, may be included in prototype projects. A prototype may be physical, virtual, or conceptual in nature. A prototype project may be fully funded by DoD, jointly funded by multiple federal agencies, cost-shared, funded in whole or part by third parties, or involve a mutual commitment of resources other than an exchange of funds.

1.2. Purpose
This solicitation, issued by the MTEC Consortium Manager (CM), Advanced Technology International (ATI), represents a Request for Project Proposals (RPP) for MTEC support of the USAMRDC’s Military Infectious Diseases Research Program (MIDRP). Military relevance is a critical component of Enhanced White Paper submission. Strategic and tactical oversight for the award(s) supported by this RPP will be provided by the MIDRP.
The goal of this RPP is to develop prototypes aimed to treat COVID-19 with the following focus area:

- **FOCUS AREA:** Therapeutic(s) that can treat COVID-19. Treatments with potential application to the prevention of COVID-19 infection are desired. Therapeutics that can be administered in a non-hospital environment are desired.

*Note: Pending successful completion of this effort, the Government may issue a non-competitive follow-on production contract or transaction pursuant to 10 USC 2371b section f.*

## 2 Administrative Overview

### 2.1. Request for Project Proposals (RPP)

Each MTEC Enhanced White Paper submitted must be in accordance with the mandatory format provided in Section 10 of the RPP.

Note that the terms Enhanced White Paper and Proposal are used interchangeably throughout this RPP.

### 2.2. Funding Availability and Type of Funding Instrument Issued

The U.S. Government (USG) Department of Defense (DoD) currently has available approximately $20 Million (M) of FY20 funds. Any potential follow-on funding is expected to be awarded non-competitively and negotiated based on outcomes, cost sharing, partner matching and estimates for additional study completion.

The anticipated Period of Performance (PoP) is up to 8 months. Dependent on the results and deliverables, additional time may be added to the period of performance for follow-on tasks.

As of the release date of this RPP, future year Defense Appropriations Bills have not been passed and there is no guarantee that any additional funds will be made available to support this program. The funding estimated for this RPP is approximate and subject to realignment. Funding of Enhanced White Papers received in response to this RPP is contingent upon the availability of federal funds for this program. Award funding will be structured incrementally and based upon completion of Milestones and Deliverables.

### 2.3. Acquisition Approach

It is expected that MTEC will make up to 5 awards to qualified teams to accomplish the statement of work. If a single Enhanced White Paper is unable to sufficiently address the entire scope of this RPP’s technical requirements (outlined in Section 5), several Offerors may be asked to work together in a collaborative manner. However, if an optimal team is not identified, then MTEC may make multiple, individual awards to Offeror(s) to accomplish subset(s) of the key tasks.
The Government-selected Awards will be funded under the Other Transaction Agreement (OTA) Number W81XWH-15-9-0001 with MTEC administered by the CM, ATI. The CM will negotiate and execute a Base Agreement with MTEC members (if not yet executed). This Base Agreement will be governed by the same provisions as the OTA between the USG and MTEC. Subsequently, any Enhanced White Paper that is selected for award is expected to be funded through a Research Project Award issued under the Base Agreement. A sample of the MTEC Base Agreement can be found on the MTEC Members-Only website at www.mtec-sc.org.

At the time of the submission, if Offerors have not yet executed a Base Agreement, then Offerors must certify on the cover page of their Enhanced White Paper that, if selected for award, they will abide by the terms and conditions of the latest version of the MTEC Base Agreement. If the Offeror already has executed an MTEC Base Agreement with the MTEC CM, then the Offeror must state on the cover page of its Enhanced White Paper that, if selected for award, it anticipates the proposed effort will be funded under its executed MTEC Base Agreement.

Offerors are advised to check the MTEC website periodically during the Enhanced White Paper preparation period for any changes to the MTEC Base Agreement terms and conditions as well as clarifications found in Frequently Asked Questions (FAQ) responses.

2.4. MTEC Member Teaming

While teaming is not required for this effort, Offerors are encouraged to consider teaming during the proposal preparation period (prior to proposal submission) if they cannot address the full scope of technical requirements of the RPP or otherwise believe a team may be beneficial to the Government. MTEC members are encouraged to use the MTEC Database Collaboration Tool. The purpose of the tool is to help MTEC member organizations identify potential teaming partners by providing a quick and easy way to search the membership for specific technology capabilities, collaboration interest, core business areas/focus, R&D highlights/projects, and technical expertise. The Primary Point of Contact for each member organization is provided access to the collaboration database tool to make edits and populate their organization’s profile. There are two sections as part of the profile relevant to teaming:

- “Collaboration Interests” - Select the type of teaming opportunities your organization would be interested in. This information is crucial when organizations need to search the membership for specific capabilities/expertise that other members are willing to offer.
- “Solicitation Collaboration Interests” - Input specific active solicitations that you are interested in teaming on. This information will help organizations interested in a specific funding opportunities identify others that are interested to partner in regards to the same funding opportunity. Contact information for each organization is provided as part of the member profile in the collaboration database tool to foster follow-up conversations between members as needed.

The Collaboration Database can be accessed via the “MTEC Profiles Site” tab on the MTEC members-only website.
Collaboration with DoD investigators is also encouraged.

2.5. Proprietary Information
The MTEC CM will oversee submission of Enhanced White Papers submitted in response to this RPP. The MTEC CM shall take the necessary steps to protect all proprietary information and shall not use such proprietary information for purposes other than the evaluation of an Offeror’s Enhanced White Paper and the subsequent agreement administration if the Proposal is selected for award. In accordance with the PPG, please mark all Confidential or Proprietary Information as such. An Offeror’s submission of a Proposal under this RPP indicates concurrence with the aforementioned CM responsibilities.

Also, as part of MTEC’s mission to incorporate philanthropic donations, MTEC frequently makes contact with private entities (e.g., foundations, investor groups, organizations, individuals) that award grants or otherwise co-fund research, and/or operates in research areas that are aligned with those of MTEC. These private entities may be interested in reviewing certain Proposals within their program areas, allowing opportunities to attract supplemental funding sources. On your Proposal Cover Page, please indicate your willingness to allow MTEC Officers and Directors access to your Proposal for the purposes of engaging in outreach activities with these private organizations. MTEC Officers and Directors granted Proposal access have signed Non-disclosure Agreements (NDAs) and Organizational Conflict of Interest (OCI) statements. Additionally, these MTEC Officers and Staff represent organizations that currently are not MTEC members, and therefore their parent organizations are not eligible to submit Proposals or receive any research project funding through MTEC. Additionally, all Technical Evaluation Panel participants will agree to, and sign a nonproprietary information and conflict of interest document.

2.6. Offeror Eligibility
MTEC membership is not required for the submission of an Enhanced White Paper in response to this upcoming MTEC RPP. However, membership will be required for Offerors recommended for award. To join MTEC, please visit http://mtec-sc.org/how-to-join/.

2.7. Inclusion of Nontraditional Defense Contractors or Nonprofit Research Institutions
Enhanced White Papers that fail to meet the mandatory statutory conditions with regard to the appropriate use of Other Transaction authority, as listed below, will not be evaluated and will determined ineligible for award. Please see the MTEC PPG and RPP (Section 5) for additional details.

Mandatory statutory conditions (the Offeror shall assert that at least one of the one of the following conditions is met):

(1) There is at least one nontraditional defense contractor or nonprofit research institution participating to a significant extent in the prototype project.
(2) All significant participants in the transaction other than the Federal Government are small businesses (including small businesses participating in a program described under section 9 of the Small Business Act (15 U.S.C. 638)) or nontraditional defense contractors.

(3) At least one third of the total cost of the prototype project is to be paid out of funds provided by sources other than the Federal Government.

The Offeror shall submit Warranties and Representations (see Attachment 2 of the PPG) specifying the critical technologies being offered and/or the significant extent of participation of the nontraditional defense contractor, small business or nonprofit research institution. The nontraditional defense contractor can be an individual so long as he/she has a DUNS Number and meets the requirements in the Warranties and Representations. The significance of the nontraditional defense contractor’s, small business’ or nonprofit research institution’s participation shall be explained in detail in the signed Warranties and Representations. Inadequate detail can cause delay in award.

Per the DoD OT Guide, rationale to justify a significant extent includes:

1. Supplying a new key technology, product or process
2. Supplying a novel application or approach to an existing technology, product or process
3. Providing a material increase in the performance, efficiency, quality or versatility of a key technology, product or process
4. Accomplishing a significant amount of the prototype project
5. Causing a material reduction in the cost or schedule of the prototype project
6. Provide for a material increase in performance of the prototype project

2.8. Nontraditional Defense Contractor Definition
A nontraditional defense contractor is a business unit that has not, for a period of at least one year prior to the issue date of the Request for Project Proposals, entered into or performed on any contract or subcontract that is subject to full coverage under the cost accounting standards (CAS) prescribed pursuant to section 26 of the Office of Federal Procurement Policy Act (41 U.S.C. 422) and the regulations implementing such section.

2.9. Cost Sharing Definition
Cost sharing is defined as the resources expended by the award recipients on the proposed statement of work (SOW). If cost sharing is proposed, then the Offeror shall state the amount that is being proposed and whether the cost sharing is a cash contribution or in-kind contribution (see below for a definition of each); provide a description of each cost share item proposed; the proposed dollar amount for each cost share item proposed; and the valuation technique used (e.g., vendor quote, historical cost, labor hours and labor rates, number of trips, etc.). Cost sharing
above the statutory minimum is encouraged if possible, as it leads to stronger leveraging of Government-contractor collaboration.

**Cash Contribution**
Cash Contribution means the Consortium and/or the Research Project Awardee (or Awardees' lower tier subawards) financial resources expended to perform a Research Project. The cash contribution may be derived from the Consortium's or Research Project Awardee (or Awardees' subawards) funds or outside sources or from nonfederal contract or grant revenues or from profit or fee on a federal procurement contract.

An Offeror’s own source of funds may include corporate retained earnings, current or prospective Independent Research and Development (IR&D) funds or any other indirect cost pool allocation. New or concurrent IR&D funds may be utilized as a cash contribution provided those funds identified by the Offeror will be spent on performance of the Statement of Work (SOW) of a Research Project or specific tasks identified within the SOW of a Research Project. Prior IR&D funds will not be considered as part of the Offeror’s cash.

Cash contributions include the funds the Offeror will spend for labor (including benefits and direct overhead), materials, new equipment (prorated if appropriate), awardees' subaward efforts expended on the SOW of a Research Project, and restocking the parts and material consumed.

**In-Kind Contribution**
In Kind Contribution means the Offeror’s non-financial resources expended by the Consortium Members to perform a Research Project such as wear-and-tear on in-place capital assets like machinery or the prorated value of space used for performance of the Research Project, and the reasonable fair market value (appropriately prorated) of equipment, materials, IP, and other property used in the performance of the SOW of the Research Project.

Prior IR&D funds will not be considered as part of the Consortium Member's cash or In-Kind contributions, except when using the same procedures as those that authorize Pre-Award Costs, nor will fees be considered on a Consortium Member’s cost sharing portion.

See the MTEC PPG for additional details. If the offer contains multiple team members, this information shall be provided for each team member providing cost share.

**2.10. MTEC Assessment Fee**
Per Section 3.4 of the Consortium Member Agreement (CMA), each recipient of a Research Project Award under the MTEC OTA shall pay MTEC an amount equal to 1% of the total funded value of each research project award. Such deposits shall be due no later than 90 days after the research project award is executed. Awardees are not allowed to use MTEC funding to pay for their assessment fees.
Additionally, MTEC has established two methods of payment to be made to MTEC surrounding the licensing/commercialization of Intellectual Property developed with funding received from MTEC Research Project Awards:

**Royalty Payment Agreements**

Government-funded research projects awarded through MTEC will be subject to a 10% royalty on all Net Revenues received by the Research Project Award recipient resulting from the licensing/commercialization of the technology, capped at 200% of the Government funding provided.

**Additional Research Project Award Assessment**

In lieu of providing the royalty payment agreement described above, members receiving Research Project Awards may elect to pay an additional assessment of 2% above the standard assessment percentage described in Section 3.4 of the CMA. This additional assessment applies to all research project awards, whether the award is Government funded or privately funded.

### 2.11. Intellectual Property and Data Rights

Intellectual Property (IP) rights for MTEC Research Project Awards will be defined in the terms of an awardee’s Base Agreement and resultant Task Orders. MTEC reserves the right to assist in the negotiation of IP, royalties, licensing, future development, etc., between the government and the individual performers during the entire award period.

The Offeror shall comply with the terms and conditions defined in the Base Agreement regarding Data Rights. **It is anticipated that anything delivered under this proposed effort will be delivered to the Government with Government purpose data rights or unlimited data rights unless otherwise asserted in the proposal and agreed to by the Government.** Rights in technical data in each Research Project Award shall be determined in accordance with the provisions of MTEC Base Agreement.

If applicable, the Offeror shall complete the below table for any items to be furnished to the Government with restrictions and include this table as Attachment C of the proposal submission. An example is provided below.

<table>
<thead>
<tr>
<th>Technical Data or Computer Software to be Furnished with Restrictions</th>
<th>Basis for Assertion</th>
<th>Asserted Rights Category</th>
<th>Name of Organization Asserting Restrictions</th>
<th>Milestone # Affected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Software XYZ</td>
<td>Previously developed software funded exclusively at private expense</td>
<td>Restricted</td>
<td>Organization XYZ</td>
<td>Milestones 1, 3, and 6</td>
</tr>
</tbody>
</table>
2.12. **Expected Award Date**
Offeror should plan on the period of performance beginning May 6, 2020 (subject to change). The Government reserves the right to change the proposed period of performance start date through negotiations via the CM and prior to issuing a Research Project Award.

2.13. **Anticipated Enhanced White Paper Selection Notification**
As the basis of selections is completed, the Government will forward their selections to MTEC CM to notify Offerors. Proposers will be notified by letter from the MTEC CM of the results of the evaluation. Those successful will move forward to the next phase of the process while those not selected will gain evaluation rationale for non-selection.

3 **Enhanced White Paper**

3.1. **Enhanced White Paper Rationale**
The MTEC will use an accelerated approach to award for this RPP. Because of the nature and urgency of the requirements set forth in this RPP, this streamlined approach is anticipated to be a better means to highlight company methodologies and skills required to address the technical requirements described herein. The Enhanced White Paper process requires extremely quick turnaround times by Offerors. The following sections describe the formats and requirements of the Enhanced White Paper.

Offerors who submit Enhanced White Papers in response to this RPP must submit by the date on the cover page of this RPP. Enhanced White Papers received after the time and date specified will not be evaluated.

3.2. **Enhanced White Paper Submission**

Do not submit any classified information in the Enhanced White Paper submission.
3.3. Submission Format
Offerors shall submit files in Microsoft Office formats or Adobe Acrobat (PDF – portable document format) as indicated below. ZIP files and other application formats are not acceptable. All files must be print-capable and without a password required. Filenames must contain the appropriate filename extension (.docx, .doc, .pptx, .ppt .xlsx, .xls or .pdf). Filenames should not contain special characters. Apple users must ensure the entire filename and path are free of spaces and special characters.

An automated BIDS receipt confirmation will be provided by email. Offerors may submit in advance of the deadline and update (or replace any of the files) up until the submission deadline. *Neither MTEC nor ATI will make allowances/exceptions for submission problems encountered by the Offeror using system-to-system interfaces. If the Offeror receives errors and fails to upload the full submission prior to the submission deadline, the submission will not be accepted. It is the Offeror’s responsibility to ensure a timely and complete submission.*

4 Enhanced White Paper Preparation Instructions

4.1. General Instructions
The Enhanced White Paper and Cost Proposal format provided in this MTEC RPP are mandatory and shall reference this RPP number (MTEC-20-09-COVID-19_Treatment_MIDRP). Offerors are encouraged to contact the Point-of-Contact (POC) identified herein up until the Enhanced White Paper submission date/time to clarify requirements.

Offerors shall submit Enhanced White Papers for evaluation according to the criteria set forth herein. Offerors are advised that only ATI as the MTEC’s CM, with the approval of the Government Agreements Officer, is legally authorized to contractually bind or otherwise commit funding for selected Awards as result of this RPP.

5 Technical Requirements

5.1. Introduction
The pandemic COVID-19, a disease caused by a novel coronavirus, continues to spread worldwide. As of March 25, 413,467 confirmed cases of COVID-19 have been reported worldwide, with 18,433 deaths from the disease ([www.who.int](http://www.who.int)), the total number of COVID-19 cases in the United States is 54,453 and total number of deaths is 737 ([www.cdc.gov](http://www.cdc.gov)). Currently, there are currently no FDA-approved vaccines or treatments for COVID-19.

5.2. Scope of Work
The goal of this RPP is to develop prototype countermeasures for the treatment of COVID-19.

- The expected TRL at start of the POP is 3/4 and at the end of the POP is TRL6
• The Offeror is expected to have at the onset a candidate therapeutic with non-clinical data (*in vitro*, tox, pre-clinical data, etc.) suggesting safety and/or efficacy
• The Offeror should have demonstrated manufacturing feasibility of the candidate therapeutic
• Offerors who have had at least one meeting with the FDA to discuss the regulatory strategy for their candidate(s) are preferred
• Repurposing commercially available, approved products or products in clinical development for related indications with demonstrated safety in humans are preferred
• Partnering with DoD investigators on pre-clinical testing in animal models is encouraged, where appropriate. [Note: Relationships with DoD laboratories must be brought forth as part of the Enhanced White Paper. MTEC members can access points of contact at Army laboratories on the members-only website.]

The expected deliverable at the end of the POP is a final technical report to support a Go/No go decision for the product to enter Phase II trials for the treatment of COVID-19 including the following:

A. Pre-Clinical Development Activities including:
   (1) Background and scientific summary of the drug or biologic, including pharmacokinetics, pharmacodynamics (PK/PD), bioavailability/equivalence, immunogenicity, mechanism of action and side effects
   (2) Summary, protocols, reports for: *in-vitro* and/or *in-vivo* pre-clinical safety toxicology animal studies, validation and qualification of assays

B. Clinical Development Activities: Summary and Results of any/all clinical studies completed

C. Future Clinical Development Plan and Regulatory Strategy
   (1) Goals and objectives for the clinical program including a list of planned clinical studies including target population, design, primary and secondary safety and efficacy endpoints, clinical protocols, and clinical trial agreements
   (2) Regulatory strategy including the regulatory pathway; target product profile or equivalent and a description of how the clinical plan will support the regulatory strategy, scheduled milestones and decision making (go/no-go) and any associated risks. A Gantt chart for product development should also be included.

D. Manufacturing Development Activities and Plan:
   Description of the manufacturing process, quality control and quality assurance plans

E. FDA Interactions:
   A list, summary, and documentation of interactions with the Food and Drug Administration in the form of meeting minutes.

5.3. Potential Follow-On Tasks
There is potential for award of one or more follow-on tasks based on the success of any resultant Research Project Awards (subject to change depending upon Government review of work completed). Note that any potential follow on work is expected to be awarded non-competitively to resultant project awardees:
- Manufacturing of therapeutics
- Further clinical testing of therapeutics

5.4. Restrictions on Animal and Human Subjects
Enhanced White Papers must comply with restrictions and reporting requirements for the use of animal and human subjects, to include research involving the secondary use of human biospecimens and/or human data. The Awardee shall ensure local Institutional Animal Care and Use Committee (IACUC) and Institutional Review Board (IRB) approvals, continuing review (in the intervals specified by the local IACUC and IRB, but at a minimum, annually), and approval by the U.S. Army Animal Use and Review Office (ACURO) and U.S. Army Human Research Protections Office (HRPO). Offerors shall include IACUC, ACURO, IRB and HRPO review and approval in the SOW/Milestones Table.

*These restrictions include mandatory government review and reporting processes that will impact the Offeror’s schedule.*

For example, the clinical studies under this RPP shall not begin until the USAMRDC Office of Research Protections (ORP) provides authorization that the research may proceed. The USAMRDC ORP will issue written approval to begin research under separate notification. Written approval to proceed from the USAMRMC ORP is also required for any Research Project Awardee (or lower tier subawards) that will use funds from this award to conduct research involving human subjects. Offerors must allow at least 60 days in their schedule for the ORP review and authorization process.

6 Enhanced White Paper Preparation

6.1. Preparation of the Enhanced White Paper
Offerors submitting Enhanced White Paper in response to this RPP will be required to submit using the following steps outlined below:

*Step 1: Enhanced White Paper*

The Offeror shall submit an Enhanced White Paper using the template provided in Section 10, which describes the overall technical concept and approach along with the viability toward the Offeror’s specific effort. Enhanced White Papers shall be submitted by the date and time specified on the cover page using BIDS:
Enhanced White Papers **exceeding the page limit specified in Section 10 of the RPP may not be accepted.**

### 6.2. Enhanced White Paper Evaluation:

1. **(1)** The CM will distribute all Enhanced White Papers to the Government for scientific and programmatic relevance evaluation.

2. **(2)** Initial Screening: The Government will perform an initial screening of the submissions. This initial screening will be based on the content of **Section 1 of the Enhanced White Paper** (see Section 10 of the RPP for the Enhanced White Paper Template). The remaining sections of the Enhanced White Paper will not be reviewed at this stage of the evaluation process – ONLY SECTION 1 of the Enhanced White Paper will be reviewed by the Government at this stage. Any Enhanced White Papers found **not** to meet the minimum acceptable qualifications as detailed below may be removed from consideration, no further evaluation will be performed, and feedback will not be provided to these Offerors. Section 1 of each Enhanced White Paper submission will be reviewed by the Government using the following criteria in order to determine if the submitted Enhanced White Paper meets the qualifications to receive a full evaluation:
   - **TRL at time of submission** - Is the proposed technology at a minimum of a TRL 3 at the time of submission?
   - **Expected TRL at end of PoP** - Does the proposed scope of work intend to advance the prototype development to a minimum of a TRL 6?
   - **Timeliness** - Does the proposed project aim to develop a therapeutic that will be able to be deployed to the field in 24 months or less?
   - **Preliminary data** - Has the Offeror provided evidence of non-clinical data to support the scientific plan and demonstrated manufacturing feasibility of the candidate therapeutic?

3. **(3)** Full Evaluation: Any Enhanced White Papers found to meet the minimum acceptable qualifications outlined in the initial screening will receive a full evaluation. Offerors will receive feedback on the full evaluation. The full evaluation of the complete Enhanced White Paper submissions will be conducted based on the following criteria (evaluation factors are of equal importance):
   - **Factor 1 - Scientific Plan**: Relevancy, thoroughness, and completeness of the proposed approach (e.g., the technical merit). This includes such factors as 1) hypothesis and objectives; 2) scientific rationale with supporting preliminary data; 3) scientific study design feasibility. The Government may consider SOW and estimated budget as an aspect of overall scientific feasibility.
   - **Factor 2 - Programmatic Relevance**: Feasibility of the proposed solution and its alignment with the RPP’s topic area and the program objective described in Section 5. How well the proposed methodology aligns with the specific focus area(s) and the overall intent of the announcement. The Government may
consider the project management plan and experience as an aspect of overall programmatic relevance.

- **Factor 3 - Regulatory and Commercialization Plan**: Feasibility of regulatory and commercialization strategy.

The Government will conduct the source selection based on the evaluation criteria listed above. The overall award decision will be based upon a Best Value determination by considering and comparing factors in addition to cost or price. See the table entitled “Table 2 - General Merit Rating Assessments” under Section 7 of this RPP for details regarding the adjectival merit ratings that will be used for the non-cost/price evaluation factors detailed above. The Offeror shall clearly state how it intends to meet and, if possible, exceed the RPP requirements. Mere acknowledgement or restatement of an RPP requirement is not acceptable.

*Upon review of the Enhanced White Papers, Offerors who are favorably evaluated may be invited for informal discussions with the Government. Offerors who are recommended for award will be required to submit a full Cost Proposal. See RPP Section 6.3 for additional details.*

### 6.3. Step 2: Cost Proposal (for Only Those Offerors Recommended for Funding)

Offerors that are recommended for funding will receive notification letters which will serve as the formal request for a full Cost Proposal (and may contain a request for Enhanced White Papers revisions based on the results of the technical evaluation). These letters will contain specific submission requirements if there are any changes to those contained in this RPP.

The Cost Proposal shall be submitted in two separate sections. One Word (.docx or .doc) or PDF file for **Section I: Cost Proposal Narrative** (see Attachment 1 of the PPG). Separately, **Section II: Cost Proposal Formats** either in Excel (.xlsx or .xls) or PDF format is required.

Each offeror selected for Step 2 will select either the **MTEC Additional Research Project Award Assessment Fee or the Royalty Payment Agreement** (available on the MTEC members only website), **not both** and submit a signed copy with the full proposal. Please see RPP Section 2.11 for additional information.

**Offerors are encouraged to use their own cost formats.** MTEC will make cost proposal formats available on the Members-Only MTEC website. The Cost Proposal formats provided in the MTEC PPG are **NOT** mandatory. Refer to the MTEC PPG for additional details.

Each cost should include direct costs and other necessary components as applicable, for example, fringe, General & Administrative Expense (G&A), Facilities & Administrative (F&A), Other Direct Costs (ODC), etc. Offerors shall provide a breakdown of material and ODC costs as applicable.

Please note that compensation to Federal personnel (civil servants or Service members) participating as human subjects (when "On-Duty"), whether or not the research is Federally funded, is **unallowable** (with the exception of some blood draws) in accordance with Department of Defense Instruction number 3216.02 (SUBJECT: Protection of Human Subjects and Adherence...
to Ethical Standards in DoD-Supported Research). You may access a full version of the DODI by accessing the following link:

6.4. Freedom of Information Act (FOIA)
To request protection from FOIA disclosure as allowed by 10 U.S.C. §2371(i), Offerors shall mark business plans and technical information with a legend identifying the documents as being submitted on a confidential basis. For more information, please refer to Section 6.1.1 of the MTEC PPG.

6.5. Enhanced White Paper and Cost Proposal Preparation Costs
The cost of preparing Enhanced White Papers and Cost Proposals in response to this RPP is not considered a direct charge to any resulting award or any other contract.

7 Selection
The CM will conduct a preliminary screening of submitted Enhanced White Papers to ensure compliance with the RPP requirements. Enhanced White Papers that do not meet these requirements may be eliminated from the competition without further review or evaluation. One of the primary reasons for non-compliance or elimination during the initial screening is the lack of significant nontraditional defense contractor participation, nonprofit research institution participation, small business participation or cost share (see RPP Section 2.8). The appropriate use of Other Transaction authority with regards to the mandatory statutory Cost Sharing or inclusion of a Nontraditional Defense Contractor, small business or nonprofit research institution participating to a significant extent determination will be made as shown in the Table below:

<table>
<thead>
<tr>
<th>TABLE 1 - APPROPRIATE USE OF OTHER TRANSACTION AUTHORITY ASSESSMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>RATING</td>
</tr>
<tr>
<td>--------</td>
</tr>
<tr>
<td>PASS</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
FAIL

Offeror proposing an MTEC research project does **NOT** meet any of the following:
- Offeror is a Nontraditional Defense Contractor or Nonprofit Research Institution
- Offeror's Enhanced White Paper has at least one Nontraditional Defense Contractor or Nonprofit Research Institution participating to a significant extent
- All significant participants in the transaction other than the Federal Government are small businesses or Nontraditional Defense Contractors
- Offeror provides at least one third of the total project cost as acceptable cost share

Based on the results of the evaluation of the Enhanced White Papers, Offerors may be selected for funding or not selected.

### 7.1 Best Value

The Government will conduct the source selection based on the evaluation criteria detailed in Section 6 of the RPP and ratings listed in Table 2. The overall award decision will be based upon a Best Value determination by considering and comparing factors in addition to cost or price. Based on the results of the evaluation, the Government reserves the right to negotiate and request changes to any or all parts of the Offeror’s proposal. Offerors will have the opportunity to concur with the requested changes, proposed further changes and revise cost proposals, as necessary.

The RPP review and award process may involve the use of contractors as subject-matter-experts or reviewers; where appropriate, the U.S. Government (USG) will employ NDAs to protect information contained in the RPP as outlined in Section 2.5.

### TABLE 2 – GENERAL MERIT RATING ASSESSMENTS

<table>
<thead>
<tr>
<th>RATING</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>OUTSTANDING</td>
<td>Proposal meets requirements and indicates an exceptional approach and understanding of the requirements. Strengths far outweigh any weaknesses. Risk of unsuccessful performance is very low.</td>
</tr>
<tr>
<td>GOOD</td>
<td>Proposal meets requirements and indicates a thorough approach and understanding of the requirements. Proposal contains strengths which outweigh any weaknesses. Risk of unsuccessful performance is low.</td>
</tr>
<tr>
<td>ACCEPTABLE</td>
<td>Proposal meets requirements and indicates an adequate approach and understanding of the requirements. Strengths and weaknesses are</td>
</tr>
</tbody>
</table>
Points-of-Contact

For inquiries, please direct your correspondence to the following contacts:

- Questions concerning contractual, cost or pricing related to this RPP should be directed to the MTEC Contracts Administrator, mtec-contracts@ati.org
- Technical and membership questions should be directed to the MTEC Director of Research, Dr. Lauren Palestrini, Ph.D., lauren.palestrini@officer.mtec-sc.org
- All other questions should be directed to the MTEC Director of Program Operations Ms. Kathy Zolman, kathy.zolman@ati.org

Once an Offeror has submitted an Enhanced White Paper, the Government and the MTEC CM will not discuss evaluation/status until the source selection process is complete.

Acronyms/Abbreviations

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACURO</td>
<td>U.S. Army Animal Use and Review Office</td>
</tr>
<tr>
<td>ATI</td>
<td>Advanced Technology International</td>
</tr>
<tr>
<td>CAS</td>
<td>Cost accounting standards</td>
</tr>
<tr>
<td>CFR</td>
<td>Code of Federal Regulations</td>
</tr>
<tr>
<td>CM</td>
<td>Consortium Manager</td>
</tr>
<tr>
<td>CMA</td>
<td>Consortium Member Agreement</td>
</tr>
<tr>
<td>DoD</td>
<td>Department of Defense</td>
</tr>
<tr>
<td>FAQ</td>
<td>Frequently Asked Questions</td>
</tr>
<tr>
<td>F&amp;A</td>
<td>Facilities and Administrative Costs</td>
</tr>
<tr>
<td>FDA</td>
<td>U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>FY</td>
<td>Fiscal Year</td>
</tr>
<tr>
<td>G&amp;A</td>
<td>General and Administrative Expenses</td>
</tr>
<tr>
<td>HRPO</td>
<td>Human Research Protections Office</td>
</tr>
<tr>
<td>IACUC</td>
<td>Institutional Animal Care and Use Committee</td>
</tr>
<tr>
<td>IP</td>
<td>Intellectual Property (e.g., patents, copyrights, licensing, etc.)</td>
</tr>
</tbody>
</table>
IRB  Institutional Review Board
IR&D  Independent Research and Development
M    Millions
MPS  Milestone Payment Schedule
MTEC Medical Technology Enterprise Consortium
NDA  Nondisclosure Agreement
OCI  Organizational Conflict of Interest
ODC  Other Direct Charges
ORP  Office of Research Protections, USAMRDC
OTA  Other Transaction Agreement
POC  Point-of-Contact
POP  Period of performance
PPG  Proposal Preparation Guide
RDA  Research, Development, and Acquisition
ROM  Rough Order of Magnitude
RPP  Request for Project Proposals
SOW  Statement of Work
USAMRDC U.S. Army Medical Research and Development Command
USG  U.S. Government, specifically the DoD
10 Enhanced White Paper Template

Page Limitation: The Enhanced White Paper is limited to thirteen (13) pages (including cover page). The following Appendices are excluded from the page limitation: (4.1) Statement of Work, (4.2) Data Rights, and (4.3) Warranties and Representations

Required Format: 12 point font (or larger), single-spaced, single-sided, 8.5 inches x 11 inches). Smaller type may be used in figures and tables, but must be clearly legible. Margins on all sides (top, bottom, left, and right) should be at least 0.5 inch.

Please note a full Cost Proposal will be requested if the Enhanced White Paper is selected for funding.
Cover Page

[Name of Offeror]
[Address of Offeror]
[Phone Number and Email Address of Offeror]

DUNS #: [DUNS #]
CAGE code: [CAGE code]

>Title of Enhanced White Paper

[Specific Requirement addressed in Enhanced White Paper]

[Offeror] certifies that, if selected for award, the Offeror will abide by the terms and conditions of the MTEC Base Agreement.

[Offeror] certifies that this Enhanced White Paper is valid for 3 years from the close of the applicable RPP, unless otherwise stated.

[A proprietary data disclosure statement if proprietary data is included. Sample:

This Enhanced White Paper includes data that shall not be disclosed outside the MTEC Consortium Management Firm and the Government and shall not be duplicated, used, or disclosed, in whole or in part, for any purpose other than to evaluate this Enhanced White Paper and negotiate any subsequent award. If, however, an agreement is awarded as a result of, or in connection with, the submission of this data, the MTEC Consortium Management Firm and the Government shall have the right to duplicate, use, or disclose these data to the extent provided in the resulting agreement. This restriction does not limit the MTEC Consortium Management Firm and the Government's right to use the information contained in these data if they are obtained from another source without restriction. The data subject to this restriction is (clearly identify) and contained on pages (insert page numbers).]
[Title of Enhanced White Paper]

SECTION 1: INITIAL SCREENING SUMMARY (2 page limit)

- Programmatic Relevance: [Provide a description of how the proposed technology needs described in this RPP.]
- TRL at time of submission: [Insert]
- Expected TRL at end of base PoP: [Insert]
- Technical Abstract: [Briefly describe project goals, hypothesis, study design, and deliverables.]
- Timeliness: [Indicate estimated time that product will be able to be deployed to the field].
- Non-Clinical Data: [Briefly describe the non-clinical data (in vitro, tox, pre-clinical data, etc.) suggesting safety and/or efficacy of the proposed therapeutic]
- Manufacturing Feasibility: [Indicate if you have demonstrated manufacturing feasibility of the candidate therapeutic. If so, briefly describe.]

SECTION 2: TECHNICAL

Section 2.1: Programmatic Relevance
- Provide the background and the Offeror’s understanding of the problem and/or technology gap/process deficiency.
- Provide a description of how the proposed technology meets the needs specified in this RPP.
- Proposed candidate therapeutic can be administered in a non-hospital environment: [Yes/No]
- Timeliness:
- Describe how quickly you will transition your technology to evaluation in humans.
- Describe how you will deploy your technology for field use.

Section 2.2: Scope Statement
- Define the scope of the effort and clearly state the objectives of the project.
- Explain if the effort is a complete solution to the requirement, or some portion thereof.

Section 2.3: Scientific Rationale / Preliminary Data
- Describe the scientific rationale for the project, including a brief description of the previous studies or preliminary data that support the feasibility of proposed work.
- Describe the non-clinical data (in vitro, tox, pre-clinical data, etc.) suggesting safety and/or efficacy of the proposed therapeutic
- Describe your demonstration of the manufacturing feasibility of the candidate therapeutic.
Section 2.4: Technical Approach

- Describe the experimental design, methods, and materials required to accomplish the proposed approach. Describe the proposed methodology in sufficient detail to show a clear course of action.
- Clinical Trials (if applicable): Clinical trials should be described in adequate detail to assess conformance with FDA regulations, guidance, and the requirements related to its appropriate pathway for development and testing.
  - Provide a description of the purpose and objectives of the study.
  - Describe the clinical intervention, medical drug, biologic, device or human exposure model to be tested. Document the availability and accessibility of the drug/compound, device, or other materials needed for the proposed research.
  - Include a description of study variables, appropriate controls and the endpoints to be tested.
  - Outline the proposed methodology (e.g., study design, data analysis, etc.) in sufficient detail to show a clear course of action. Describe potential challenges and alternative strategies where appropriate.
  - Describe current status of interactions with the U.S. Food and Drug Administration and your plan to meet all regulatory sponsor responsibilities.

Section 2.5: Anticipated Outcomes

- Provide a description of the anticipated outcomes from the proposed work. List milestones and deliverables from the proposed work.

Section 2.6: Team

- Describe the qualifications and expertise of the key personnel and organizations that will perform the proposed work.
- Indicate which organizations or types of organizations you will need to team/partner with as your technology advances into clinical evaluation and/or field use.

Section 2.7: Project Management Plan

- Describe the overall project management plan.

Section 2.8: Regulatory and Commercialization Plan

- Briefly describe the regulatory plan, including FDA pathway and designation, strategy for obtaining FDA approvals or clearances.
- Briefly describe the transition and commercialization plan, including a description of the market (civilian and military) and sustainability.

Section 2.9: Resources
• Identify any key facilities, equipment and other resources proposed for the effort. Identified facilities, equipment and resources should be available and relevant for the technical solution being proposed.

Section 2.10: Schedule
• Period of Performance: Indicate the proposed period of performance in months from award.
• Proposed Schedule: Provide a schedule (e.g. Gantt chart) that clearly shows the plans to perform the program tasks in an orderly, timely manner. Provide each major task as a separate line.

Section 2.11: Risk Identification and Mitigation
• Identify key technical, schedule, and cost risks. Discuss the potential impact of the risks, as well as potential mitigations.

SECTION 3: COST ESTIMATE

Section 3.1: Estimate Summary
• The Offeror must provide an estimate based on the technical approach proposed in the Enhanced White Paper. The following chart (tailored as appropriate) shall be included in the Enhanced White Paper. If selected for award, a full cost proposal will be requested.

<table>
<thead>
<tr>
<th>Year</th>
<th>Estimate</th>
<th>Cost Share Estimate (if applicable)</th>
<th>Total Estimate (w/ Cost Share)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year 1</td>
<td>$</td>
<td>$</td>
<td>$</td>
</tr>
<tr>
<td>Year 2 (if applicable)</td>
<td>$</td>
<td>$</td>
<td>$</td>
</tr>
<tr>
<td>Year 3 (if applicable)</td>
<td>$</td>
<td>$</td>
<td>$</td>
</tr>
<tr>
<td>TOTAL</td>
<td>$</td>
<td>$</td>
<td>$</td>
</tr>
</tbody>
</table>

Section 3.2: Estimate Rationale
• The Offeror must provide a brief rationale describing how the estimate was calculated and is appropriate for the proposed scope or approach.

SECTION 4: APPENDICES (excluded from the page limit)

Appendix 4.1: Statement of Work
• Provide a draft Statement of Work as a separate Word document to outline the proposed technical solution and demonstrate how the contractor proposes to meet the Government objectives. Submitted information is subject to change through negotiation if the Government selects the Enhanced White Paper for award. The format of the proposed Statement of Work shall be completed in accordance with the template provided below.
• The Government reserves the right to negotiate and revise any or all parts of SOW/Milestone Payment Schedule. Offerors will have the opportunity to concur with revised SOW/Milestone Payment Schedule as necessary.

**Appendix 4.2: Data Rights Assertions**

• The Offeror shall comply with the terms and conditions defined in the Base Agreement regarding Data Rights. It is anticipated that anything delivered under this proposed effort would be delivered to the Government with Government Purpose Data Rights or Unlimited Data Rights.

• If this is not the intent, then you should discuss any restricted data rights associated with any proposed deliverables. If applicable, complete the below table for any items to be furnished to the Government with restrictions. An example is provided.

**Appendix 4.3: Warranties and Representations:**

• Warranties and Representations are required. One Word (.docx or .doc) or PDF file that contains all Warranties and Representations is required.

**SECTION 5: APPENDIX TEMPLATES**

**Appendix 5.1: Statement of Work**

The SOW developed by the Lead MTEC member organization and included in the proposal (also submitted as a separate document) is intended to be incorporated into a binding agreement if the proposal is selected for award. If no SOW is submitted with the proposal, there may be no award. The proposed SOW shall contain a summary description of the technical methodology as well as the task description, but not in so much detail as to make the contract inflexible. DO NOT INCLUDE ANY PROPRIETARY INFORMATION OR COMPANY-SENSITIVE INFORMATION IN THE SOW TEXT. The following is the required format for the SOW.

**Proposal Number:**

**Organization:**

**Title:**

**ACURO and/or HRPO approval needed:**

**Introduction/Background** *(To be provided initially by the Offeror at the time of proposal submission. Submitted information is subject to change through negotiation if the Government selects the proposal for funding.)*

**Scope/Project Objective** *(To be provided initially by the Offeror at the time of proposal submission. Submitted information is subject to change through negotiation if the Government selects the proposal for funding.)*
This section includes a statement of what the project covers. This should include the technology area to be investigated, the objectives/goals, and major milestones for the effort.

**Requirements** *(To be provided initially by the Offeror at the time of proposal submission to be finalized by the Government based on negotiation of Scope/Project Objective)*.

State the technology objective in the first paragraph and follow with delineated tasks required to meet the overall project goals. The work effort should be segregated into major phases, then tasks and identified in separately numbered paragraphs (similar to the numbered breakdown of these paragraphs). Early phases in which the performance definition is known shall be detailed by subtask with defined work to be performed. Planned incrementally funded phases will require broader, more flexible tasks that are priced up front, and adjusted as required during execution and/or requested by the Government to obtain a technical solution. Tasks will need to track with established adjustable cost or fixed price milestones for payment schedule. Each major task included in the SOW should be priced separately in the cost proposal. Subtasks need not be priced separately in the cost proposal.

**Deliverables** *(To be provided initially by the Offeror at the time of proposal submission. Submitted information is subject to change through negotiation if the Government selects the proposal for funding.)*

Results of the technical effort are contractually binding and shall be identified herein. Offerors are advised to read the Base Agreement carefully. Any and all hardware/software to be provided to the Government as a result of this project shall be identified. Deliverables should be submitted in PDF or MS Office format. It must be clear what information will be included in a deliverable either through a descriptive title or elaborating text.

**Milestone Payment Schedule** *(To be provided initially by the Offeror at the time of proposal submission. Submitted information is subject to change through negotiation if the Government selects the proposal for funding. The milestone schedule included should be in editable format (i.e., not a picture))*

The Milestone Payment Schedule should include all milestone deliverables that are intended to be delivered as part of the project, a planned submission date, the monetary value for that deliverable and any cost share, if applicable. For fixed price agreements, when each milestone is submitted, the MTEC member will submit an invoice for the exact amount listed on the milestone payment schedule. For cost reimbursable agreements, the MTEC member is required to assign a monetary value to each milestone. In this case, however, invoice totals are based on cost incurred and will not have to match exactly to the amounts listed on the milestone payment schedule. The milestones and associated deliverables proposed should, in general:

- be commensurate in number to the size and duration of the project (i.e., a $5M multi-year project may have 20, while a $700K shorter term project may have only 6);
- not be structured such that multiple deliverables that might be submitted separately are included under a single milestone;
• be of sufficient monetary value to warrant generation of a deliverable and any associated invoices;
• include at a minimum Quarterly Reports which include both Technical Status and Business Status Reports (due the 25th of Apr, Jul, Oct, Jan), Annual Technical Report, Final Technical Report, and Final Business Status Report. Reports shall have no funding associated with them.

### MTEC Milestone Payment Schedule Example

<table>
<thead>
<tr>
<th>MTEC Milestone Number</th>
<th>Task Number</th>
<th>Significant Event/ Accomplishments</th>
<th>Due Date</th>
<th>Government Funds</th>
<th>Cost Share</th>
<th>Total Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>N/A</td>
<td>Project Kickoff</td>
<td>12/1/2019</td>
<td>$20,000</td>
<td></td>
<td>$20,000</td>
</tr>
<tr>
<td>2</td>
<td>N/A</td>
<td>Quarterly Report 1 (October - December, Technical and Business Reports)</td>
<td>1/25/2020</td>
<td>$ -</td>
<td></td>
<td>$ -</td>
</tr>
<tr>
<td>3</td>
<td>1</td>
<td>Protocol Synopsis</td>
<td>2/28/2020</td>
<td>$21,075</td>
<td></td>
<td>$21,075</td>
</tr>
<tr>
<td>4</td>
<td>2</td>
<td>Submission for HRPO Approval</td>
<td>2/28/2020</td>
<td>$21,075</td>
<td></td>
<td>$21,075</td>
</tr>
<tr>
<td>5</td>
<td>3</td>
<td>Submission of Investigational New Drug application to the US FDA</td>
<td>4/30/2020</td>
<td>$210,757</td>
<td>$187,457</td>
<td>$398,214</td>
</tr>
<tr>
<td>6</td>
<td>N/A</td>
<td>Quarterly Reports 2 (January - March, Technical and Business Reports)</td>
<td>4/25/2020</td>
<td>$ -</td>
<td></td>
<td>$ -</td>
</tr>
<tr>
<td>7</td>
<td>N/A</td>
<td>Quarterly Report 3 (April - June, Technical and Business Reports)</td>
<td>7/25/2020</td>
<td>$ -</td>
<td></td>
<td>$ -</td>
</tr>
<tr>
<td>8</td>
<td>4</td>
<td>Toxicity Studies</td>
<td>10/1/2020</td>
<td>$63,227</td>
<td></td>
<td>$63,227</td>
</tr>
<tr>
<td>9</td>
<td>N/A</td>
<td>Annual Report 1</td>
<td>10/25/2020</td>
<td>$ -</td>
<td></td>
<td>$ -</td>
</tr>
<tr>
<td>10</td>
<td>5</td>
<td>FDA authorization trial</td>
<td>11/30/2020</td>
<td>$84,303</td>
<td></td>
<td>$84,303</td>
</tr>
<tr>
<td>11</td>
<td>6</td>
<td>Research staff trained</td>
<td>11/30/2020</td>
<td>$ -</td>
<td></td>
<td>$ -</td>
</tr>
<tr>
<td>12</td>
<td>7</td>
<td>Data Management system completed</td>
<td>11/30/2020</td>
<td>$ -</td>
<td></td>
<td>$ -</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>8</td>
<td>1&lt;sup&gt;st&lt;/sup&gt; subject screened, randomized and enrolled in study</td>
<td>1/1/2021</td>
<td>$150,000</td>
<td>$187,457</td>
<td>$337,457</td>
</tr>
<tr>
<td>14</td>
<td>N/A</td>
<td>Quarterly Report 4 (October - December, Technical and Business Reports)</td>
<td>1/25/2021</td>
<td>$ -</td>
<td>$ -</td>
<td>$ -</td>
</tr>
<tr>
<td>15</td>
<td>9</td>
<td>Completion of dip molding apparatus</td>
<td>3/1/2021</td>
<td>$157,829</td>
<td>$187,457</td>
<td>$345,286</td>
</tr>
<tr>
<td>16</td>
<td>N/A</td>
<td>Quarterly Reports 5 (January - March, Technical and Business Reports)</td>
<td>4/25/2021</td>
<td>$ -</td>
<td>$ -</td>
<td>$ -</td>
</tr>
<tr>
<td>17</td>
<td>10</td>
<td>Assess potential toxicology</td>
<td>6/1/2021</td>
<td>$157,829</td>
<td>$157,829</td>
<td>$ -</td>
</tr>
<tr>
<td>18</td>
<td>N/A</td>
<td>Quarterly Report 6 (April - June, Technical and Business Reports)</td>
<td>7/25/2021</td>
<td>$ -</td>
<td>$ -</td>
<td>$ -</td>
</tr>
<tr>
<td>19</td>
<td>11</td>
<td>Complete 50% patient enrollment</td>
<td>10/1/2021</td>
<td>$350,000</td>
<td>$187,457</td>
<td>$537,457</td>
</tr>
<tr>
<td>20</td>
<td>N/A</td>
<td>Annual Report 1</td>
<td>10/25/2021</td>
<td>$ -</td>
<td>$ -</td>
<td>$ -</td>
</tr>
<tr>
<td>21</td>
<td>N/A</td>
<td>Quarterly Report 7 (October - December, Technical and Business Reports)</td>
<td>1/25/2022</td>
<td>$ -</td>
<td>$ -</td>
<td>$ -</td>
</tr>
<tr>
<td>23</td>
<td>N/A</td>
<td>Quarterly Reports 8 (January - March, Technical and Business Reports)</td>
<td>4/25/2022</td>
<td>$ -</td>
<td>$ -</td>
<td>$ -</td>
</tr>
<tr>
<td>24</td>
<td>N/A</td>
<td>Quarterly Report 9 (April - June, Technical and Business Reports)</td>
<td>7/25/2022</td>
<td>$ -</td>
<td>$ -</td>
<td>$ -</td>
</tr>
<tr>
<td>25</td>
<td>13</td>
<td>Complete 100% patient enrollment</td>
<td>8/1/2022</td>
<td>$315,658</td>
<td>$187,457</td>
<td>$503,115</td>
</tr>
<tr>
<td>26</td>
<td>N/A</td>
<td>Annual Report 1</td>
<td>10/25/2022</td>
<td>$ -</td>
<td>$ -</td>
<td>$ -</td>
</tr>
<tr>
<td>27</td>
<td>14</td>
<td>Report results from data analysis</td>
<td>11/1/2022</td>
<td>$157,829</td>
<td>$157,829</td>
<td>$ -</td>
</tr>
</tbody>
</table>
Please Note:

1. Firm Fixed Price Contracts – Milestone must be complete before invoicing for fixed priced contracts.
2. Cost Reimbursable Contracts – You may invoice for costs incurred against a milestone. Invoicing should be monthly.
3. Cannot receive payment for a report (i.e. Quarterly, Annual and Final Reports should not have an assigned Government Funded or Cost Share amount.)
4. Quarterly and Annual Reports include BOTH Technical and Business Reports (separate).
5. Final Report due date must be prior to POP end noted in subcontract.
6. MTEC Milestone Numbers are used for administrative purposes and should be sequential.
7. Task Numbers are used to reference the statement of work if they are different from the MTEC Milestone Number.

Shipping Provisions *(The following information, if applicable to the negotiated SOW, will be finalized by the Government and the MTEC Consortium Manager based on negotiations)*

The shipping address is:
- Classified Shipments:
  - Outer Packaging
  - Inner Packaging

Reporting

<table>
<thead>
<tr>
<th>Report Months</th>
<th>Due Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>January – March</td>
<td>25 April</td>
</tr>
<tr>
<td>April - June</td>
<td>25 July</td>
</tr>
<tr>
<td>July - September</td>
<td>25 October</td>
</tr>
<tr>
<td>October - December</td>
<td>25 January</td>
</tr>
</tbody>
</table>

Quarterly Reports – The MTEC research project awardee shall prepare a Quarterly Report which will include a Technical Status Report and a Business Status Report in accordance with the terms and conditions of the Base Agreement. (Required)

Annual Technical Report – The project awardee shall prepare an Annual Technical Report for projects whose periods of performances are greater than one year in accordance with the terms and conditions of the Base Agreement. (Required)

Final Technical Report – At the completion of the Research Project Award, the awardee will submit a Final Technical Report, which will provide a comprehensive, cumulative, and...
substantive summary of the progress and significant accomplishments achieved during the total period of the Project effort in accordance with the terms and conditions of the Base Agreement. (Required)

Final Business Status Report – At the completion of the Research Project Award, the awardee will submit a Final Business Status Report, which will provide summarized details of the resource status of the Research Project Award, in accordance with the terms and conditions of the Base Agreement. (Required)

Appendix 5.2: Data Rights Assertions

Data Rights
The Offeror shall comply with the terms and conditions defined in the Base Agreement regarding Data Rights.

It is anticipated that anything delivered under this proposed effort would be delivered to the Government with **Government purpose data rights** or **unlimited data rights**. If this is not the intent, then the proposal should discuss data rights associated with each item, and possible approaches for the Government to gain Government purpose data rights or unlimited data rights as referenced in the Base Agreement. Rights in technical data in each Research Project Award shall be determined in accordance with the provisions of MTEC Base Agreement.

If applicable, complete the below table for any items to be furnished to the Government with restrictions. An example is provided.

**Please indicate your assertion:**

- □ Unlimited Data Rights.
- □ Government Purpose Data Rights.
- □ Restricted Government Rights as described below.

<table>
<thead>
<tr>
<th>Technical Data or Computer Software to be Furnished with Restrictions</th>
<th>Basis for Assertion</th>
<th>Asserted Rights Category</th>
<th>Name of Organization Asserting Restrictions</th>
<th>Milestone # Affected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Software XYZ</td>
<td>Previously developed software funded exclusively at private expense</td>
<td>Restricted</td>
<td>Organization XYZ</td>
<td>Milestones 1, 3, and 6</td>
</tr>
<tr>
<td>Technical Data Description</td>
<td>Previously developed exclusively at private expense</td>
<td>Limited</td>
<td>Organization XYZ</td>
<td>Milestone 2</td>
</tr>
</tbody>
</table>
Appendix 5.3: Warranties and Representations:
Authority to use Other Transaction Agreement

Section 815 of the National Defense Authorization Act (NDAA) for Fiscal Year 2018, authorizes Department of Defense organizations to carry out prototype projects that are directly relevant to enhancing the mission effectiveness of military personnel and the supporting platforms, systems, components, or materials proposed to be acquired or developed by the Department of Defense, or to improvement of platforms, systems, components, or materials in use by the armed forces. The law also requires:

(A) There is at least one nontraditional defense contractor or nonprofit research institution participating to a significant extent in the prototype project.

(B) All significant participants in the transaction other than the Federal Government are small businesses (including small businesses participating in a program described under section 9 of the Small Business Act (15 U.S.C. 638)) or nontraditional defense contractors.

(C) At least one third of the total cost of the prototype project is to be paid out of funds provided by sources other than the Federal Government.

A. Prime Contractor: The prime contractor must complete the following table.

<table>
<thead>
<tr>
<th>1. Legal Name:</th>
<th>2. DUNS #:</th>
</tr>
</thead>
<tbody>
<tr>
<td>3. Point of Contact: Name, Title, Phone #, Email</td>
<td></td>
</tr>
<tr>
<td>4. Prime Contractor is a nontraditional (Y/N)?</td>
<td></td>
</tr>
<tr>
<td>5. Prime Contractor is a nonprofit research institution (Y/N)?</td>
<td></td>
</tr>
<tr>
<td>6. Prime Contractor will provide at least one third of the total cost of the prototype project out of funds provided by sources other than the Federal Government (Y/N)?</td>
<td></td>
</tr>
<tr>
<td>7. Prime Contractor is a small business (Y/N)?</td>
<td></td>
</tr>
</tbody>
</table>

If the prime contractor has answered “Y” to question 4, 5, or 6, skip Section B and proceed to Section C.

B. Subcontractor(s)/Vendor(s): If the prime contractor is a traditional defense contractor and proposes the use of one or more nontraditional defense contractors or nonprofit research institutions, the following information is required for each participating nontraditional defense contractor or nonprofit research institution.

<table>
<thead>
<tr>
<th>8. Legal Name:</th>
<th>9. DUNS #:</th>
</tr>
</thead>
<tbody>
<tr>
<td>10. Dollar Value to be Awarded to Subcontractor:</td>
<td></td>
</tr>
</tbody>
</table>
|   | 11. Point of Contact:  
<table>
<thead>
<tr>
<th></th>
<th>(Name, Title, Phone #, Email)</th>
<th>12. Task/Phase:</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.</td>
<td>Subcontractor/Vendor is a nontraditional (Y/N)?</td>
<td></td>
</tr>
<tr>
<td>14.</td>
<td>Subcontractor/Vendor is a nonprofit research institution (Y/N)?</td>
<td></td>
</tr>
<tr>
<td>15.</td>
<td>Subcontractor/Vendor is a small business (Y/N)?</td>
<td></td>
</tr>
<tr>
<td>16.</td>
<td>Significant Contribution:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A - The significant contribution involves developing, demonstrating or providing a key technology. Please describe what the key technology is; why it is key to the medical technology community, and what makes it key.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>B - The significant contribution involves developing, demonstrating or providing a new technology that is not readily available. Please describe what the new part or material is and why it is not readily available.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C - The significant contribution involves use of skilled personnel (such as modeling &amp; simulation experience, medical technology design experience, etc.), facilities and/or equipment that are within the capabilities of the designated nontraditional and required to successfully complete the program. Please describe the personnel, facilities and/or equipment involved in the proposed program and why they are required to successfully complete the program.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D - The use of this designated subcontractor/vendor will cause a material reduction in the cost or schedule. Please describe the specific cost or schedule impact to be realized</td>
<td></td>
</tr>
<tr>
<td></td>
<td>E - The use of this designated subcontractor/vendor will increase medical technology performance. Please describe what the performance increase will be attained by the use of this designated nontraditional defense contractor</td>
<td></td>
</tr>
</tbody>
</table>

1. In addition to the above please provide the following information:

Q1 What additional capability beyond those described in A through E above does this subcontractor/vendor have that is necessary for this specific effort?

A1

Q2 In which task/phase(s) of the effort will the subcontractor/vendor be used?

A2

Q3 What is the total estimated cost associated with the subcontractor/vendor included in the proposal? Note: While cost is an indicator for the level of nontraditional defense contractor participation, there is no particular cost threshold required.

A3
C. Signature

_________________________________________________________  
Signature of authorized representative of proposing Prime Contractor  

___________________________  
Date
Warranties and Representations Instructions

Section A must be completed for the Prime Contractor.
1. Insert prime contractor’s legal name.
2. Insert prime contractor’s DUNS #.
3. Insert the Point of Contact (Name, Title, Phone #, Email) for the prime contractor.
4. Indicate Yes (Y) or No (N) if the prime contractor is a nontraditional defense contractor (Note: A nontraditional defense contractor means an entity that is not currently performing and has not performed, for at least the one-year period preceding the issue date of the solicitation, any contract or subcontract for the Department of Defense that is subject to full coverage under the cost accounting standards prescribed pursuant to Section 1502 of Title 41 and the regulations implementing such section.).
5. Indicate Yes (Y) or No (N) if the prime contractor is a nonprofit research institution.
6. Indicate Yes (Y) or No (N) if the prime contractor will provide at least one third of the total cost of the prototype project out of funds provided by sources other than the Federal Government (i.e. will the project contain at least 1/3 cost share).
7. Indicate Yes (Y) or No (N) if the prime contractor is a small business (including small businesses participating in a program described under section 9 of the Small Business Act (15 U.S.C. 638)).

Section B must be completed if the Prime Contractor is traditional and has proposed nontraditional defense contractors, nonprofit research institutions, or small businesses. Copy, paste, and complete the table found in Section B for each participating nontraditional defense contractor, nonprofit research institutions, or small business.
8. Insert subcontractor/vendor’s legal name.
9. Insert subcontractor/vendor’s DUNS #.
10. Insert the dollar value (cost and fee) to be awarded to the subcontractor/vendor.
11. Insert the Point of Contact (Name, Title, Phone #, Email) for the subcontractor/vendor.
12. Indicate in which specific task/phase(s) of the effort will the subcontractor/vendor be used.
13. Indicate Yes (Y) or No (N) if the subcontractor/vendor is a nontraditional defense contractor (Note: A nontraditional defense contractor means an entity that is not currently performing and has not performed, for at least the one-year period preceding the issue date of the solicitation, any contract or subcontract for the Department of Defense that is subject to full coverage under the cost accounting standards prescribed pursuant to Section 1502 of Title 41 and the regulations implementing such section.).
14. Indicate Yes (Y) or No (N) if the subcontractor/vendor is a nonprofit research institution.
15. Indicate Yes (Y) or No (N) if the subcontractor/vendor is a small business (including small businesses participating in a program described under section 9 of the Small Business Act (15 U.S.C. 638)).
16. Explain the subcontractor/vendor’s Significant Contribution to the project by answering the questions below.
A - The significant contribution involves developing, demonstrating or providing a key technology. Please describe what the key technology is; why it is key to the medical technology community, and what makes it key.

B - The significant contribution involves developing, demonstrating or providing a new technology that is not readily available. Please describe what the new part or material is and why it is not readily available.

C - The significant contribution involves use of skilled personnel (such as modeling & simulation experience, medical technology design experience, etc.), facilities and/or equipment that are within the capabilities of the designated nontraditional and required to successfully complete the program. Please describe the personnel, facilities and/or equipment involved in the proposed program and why they are required to successfully complete the program.

D - The use of this designated subcontractor/vendor will cause a material reduction in the cost or schedule. Please describe the specific cost or schedule impact to be realized.

E - The use of this designated subcontractor/vendor will increase medical technology performance. Please describe what the performance increase will be attained by the use of this designated nontraditional defense contractor.

Q1 - What additional capability beyond those described in A through E above does this subcontractor/vendor have that is necessary for this specific effort?

Q2 - In which task/phase(s) of the effort will the subcontractor/vendor be used?

Q3 - What is the total estimated cost associated with the subcontractor/vendor included in the proposal? Note: While cost is an indicator for the level of nontraditional defense contractor participation, there is no particular cost threshold required.

Section C must be signed by an authorized representative of the prime contractor.

**General Guidance**

- Nontraditional defense contractors can be at the prime level, team members, subcontractors, lower tier vendors, or "intra-company" business units, provided that the business unit makes a significant contribution to the prototype project.
- All nontraditional defense contractors must have a DUNS number.
- A foreign business can be considered a nontraditional if it has a DUNS number and can comply with the terms and conditions of the MTEC Base Agreement.